Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Preliminary efficacy and safety results from the TATCIST trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer
Full Poster Download Preliminary efficacy and safety results from the TATCIST trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer The post Preliminary efficacy a
Read more
Report
Fusion Pharma climbs as analysts flag radiopharmaceutical company as potential merger target
Read more
Report
FPI-2068: A novel anti-EGFR/cMET, alpha-particle emitting, radioimmunoconjugate for cancer therapy
Full Poster Download FPI-2068: A novel anti-EGFR/cMET, alpha-particle emitting, radioimmunoconjugate for cancer therapy The post FPI-2068: A novel anti-EGFR/cMET, alpha-particle emitting, radioimmunoconjugate for cancer therapy appeared first on Fusion Ph
Read more
Report
Dose-Escalation Study of 225Ac-FPI-1434 in Patients With IGF-1R-Expressing Advanced Solid Tumors: Preliminary Pharmacology and Dosimetry Results
Full Poster Download Dose-Escalation Study of 225Ac-FPI-1434 (FPI-1434) in Patients With IGF-1R-Expressing Advanced Solid Tumors: Preliminary Pharmacology and Dosimetry Results The post Dose-Escalation Study of 225Ac-FPI-1434 in Patients With IGF-1R-Expre
Read more
Report
EGFRvIII-Targeted Alpha Therapy Shows Significant Therapeutic Efficacy as Both a Single-Agent and in Combination with Standard of Care Against Preclinical GBM Models
Full Poster Download EGFRvIII-Targeted Alpha Therapy Shows Significant Therapeutic Efficacy as Both a Single-Agent and in Combination with Standard of Care Against Preclinical GBM Models The post EGFRvIII-Targeted Alpha Therapy Shows Significant Therapeut
Read more
Report
TEM-1 Targeted Alpha Therapeutic 225Ac-FPI-1848 Induces Regression in Pre-Clinical Sarcoma Xenograft Models
Full Poster Download TEM-1 targeted alpha therapeutic 225Ac-FPI-1848 induces regression in pre-clinical sarcoma xenograft models The post TEM-1 Targeted Alpha Therapeutic 225Ac-FPI-1848 Induces Regression in Pre-Clinical Sarcoma Xenograft Models appeared
Read more
Report
NTSR1-targeted Alpha Therapeutic 225Ac-FPI-2059 Induces Growth Inhibition in a Preclinical Colorectal Tumor Model
Full Poster Download NTSR1-targeted Alpha Therapeutic 225Ac-FPI-2059 Induces Growth Inhibition in a Preclinical Colorectal Tumor Model The post NTSR1-targeted Alpha Therapeutic 225Ac-FPI-2059 Induces Growth Inhibition in a Preclinical Colorectal Tumor Mod
Read more
Report
Adaptation of an Investigational β-Emitting NTSR1-Targeted Radiopharmaceutical into the Targeted Alpha Therapeutic 225Ac-FPI-2059
Full Poster Download Adaptation of an Investigational β-Emitting NTSR1-Targeted Radiopharmaceutical into the Targeted Alpha Therapeutic 225Ac-FPI-2059 The post Adaptation of an Investigational β-Emitting NTSR1-Targeted Radiopharmaceutical into the Targete
Read more
Report
Impact of Pre-Administration of Anti-IGF-1R Antibody FPI-1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent 111In-FPI-1547 in Patients with Solid Tumors
Full Presentation Download Impact of Pre-Administration of Anti-IGF-1R Antibody FPI-1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent 111In-FPI-1547 in Patients with Solid Tumors The post Impact of
Read more
Report
NTSR1 Targeted Alpha Therapeutic 225Ac-FPI-2059 Induces Regression in Preclinical Colorectal Xenograft Model
Full Presentation Download NTSR1 Targeted Alpha Therapeutic 225Ac-FPI-2059 Induces Regression in Preclinical Colorectal Xenograft Model The post NTSR1 Targeted Alpha Therapeutic 225Ac-FPI-2059 Induces Regression in Preclinical Colorectal Xenograft Model a
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Hamilton
Canada
Regional office
Get in touch.
